Emmes, a global Clinical Research Organization (CRO) on a mission to revolutionize public health and biopharmaceutical innovation, has taken a bold step forward with the acquisition of Essex Management. Essex is a renowned provider of bioinformatics and health information technology (HIT) consulting services to government, private sector, and academic organizations.
This acquisition is a game-changer for Emmes, allowing it to provide clients with the most innovative solutions and expand its services. With the addition of Essex, Emmes will now be able to explore uncharted territories in clinical research and provide cutting-edge data strategies for biopharma clients.
The merger of Emmes and Essex will result in a clinical research powerhouse that’s unmatched in the industry. With the combined strength of Emmes’ advanced analytics solutions and Essex’s technology skills, the CRO will be better equipped to tackle global health challenges and pave the way for a new era of clinical research.
Essex’s reputation as a technology catalyst in the life sciences, combined with Emmes’ successful partnerships with the National Cancer Institute (NCI) and other public sector clients, will ignite a spark that will drive growth and bring a new level of innovation to clinical research.